ASCO 2022: ENZAMET Update Confirms Overall Survival Benefit to Adding Enzalutamide to Testosterone Suppression for Metastatic Prostate Cancer
Benefits were apparent even among patients who received docetaxel
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.